Journal article
Expression of miR-210 in relation to other measures of hypoxia and prediction of benefit from hypoxia modification in patients with bladder cancer
- Abstract:
-
The addition of hypoxia modifiers carbogen and nicotinamide (CON) to radiotherapy (RT) improved overall survival (OS) in bladder cancer patients in the BCON phase III clinical trial. We investigate whether expression of hsa-miR-210 in BCON patient samples reflects hypoxia and predicts benefit from hypoxia modification.In all, 183 T1-T4a bladder cancer samples were available for miR-210 analysis. A total of 86 received RT+CON and 97 received RT alone. TaqMan qPCR plates were used to assess miR...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 744.4KB, Terms of use)
-
- Publisher copy:
- 10.1038/bjc.2016.218
Authors
Funding
Bibliographic Details
- Publisher:
- Cancer Research UK
- Journal:
- British journal of cancer More from this journal
- Volume:
- 115
- Issue:
- 5
- Pages:
- 571-578
- Publication date:
- 2016-07-21
- Acceptance date:
- 2016-06-15
- DOI:
- EISSN:
-
1532-1827
- ISSN:
-
0007-0920
- Pmid:
-
27441495
Item Description
- Language:
-
English
- Keywords:
- Pubs id:
-
pubs:635003
- UUID:
-
uuid:ead72bdb-f1c9-458a-b78f-f073c375676b
- Local pid:
-
pubs:635003
- Source identifiers:
-
635003
- Deposit date:
-
2017-06-14
Terms of use
- Copyright holder:
- © 2016 Cancer Research UK
- Copyright date:
- 2016
- Notes:
-
This work is licensed under the Creative Commons Attribution 4.0 International License.
To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
- Licence:
- CC Attribution (CC BY)
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record